IL1A and type 1 diabetes mellitus: Among the proinflammatory cytokines, IL-1, long known to directly cause β-cell dysfunction and death, has been the target for T1D therapy in several major clinical trials including the Anti-Interleukin-1 in Diabetes Action (AIDA) and TrialNet Canakinumab (TN-14) trials [28, 29].